Clopidogrel loading — Competitive Intelligence Brief

Clopidogrel loading (Clopidogrel loading) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Clopidogrel loading (Clopidogrel loading) — Azienda Policlinico Umberto I. Clopidogrel is a prodrug that irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel loading TARGET	Clopidogrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
CYP2C19 Genotype Guided DAPT	CYP2C19 Genotype Guided DAPT	Zunyi Medical College	marketed	Pharmacogenomic-guided antiplatelet therapy strategy	CYP2C19 enzyme; P2Y12 receptor (indirect)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

1. Azienda Policlinico Umberto I · 1 drug in this class
2. Hospital Central San Luis Potosi, Mexico · 1 drug in this class
3. Sanofi · 1 drug in this class
4. Seung-Jung Park · 1 drug in this class
5. Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
6. US Department of Veterans Affairs · 1 drug in this class
7. University of Pecs · 1 drug in this class
8. VA Office of Research and Development · 1 drug in this class